Drug Trial Radar · NCT06127407
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jul 9, 2024
Primary completion
Feb 1, 2028
Study completion Nov 26, 2030
Sponsor
- Lead sponsor
- Servier Bio-Innovation LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Institut de Recherches Internationales Servier
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must have radiographic progression/recurrence of disease according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and have received 0 to 2 prior systemic treatment regimens in the advanced/metastatic setting for conventional chondrosarcoma. The primary endpoint is progression-free survival (PFS) in Grades 1 and 2 participants. Key secondary endpoints are PFS in all randomized participants, overall survival (OS) in Grades 1 and 2 participants, and OS in all randomized participants. Participants who meet enrollment criteria will be randomized 1:1 to receive oral ivosidenib 500mg once daily, or a matching placebo once daily.
Conditions
- Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions
Ivosidenib 500mgDrug
Provided as tablets, taken orally as two 250mg tablets once daily.
PlaceboDrug
Provided as tablets, taken orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) based on Blinded Independent Central Reviewer (BICR) assessment in Grade 1 and Grade 2 participantsTime frame: Up to approximately 31 months
Locations
115 sites in 17 countries. Site status is shown where the registry gives one.
Usc Norris Comprehensive Cancer Center
Los Angeles, California · Terminated
Sarcoma Oncology Research Center
Santa Monica, California · Recruiting
University of Colorado Cancer Center
Aurora, Colorado · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Mayo Clinic - Jacksonville, Fl
Jacksonville, Florida · Recruiting
University of Miami
Miami, Florida · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois · Recruiting
University of Iowa Hospitals & Clinics- Holden Comprehensive Cancer Center
Iowa City, Iowa · Recruiting
Johns Hopkins University
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic - Rochester, Mn
Rochester, Minnesota · Recruiting
The Washington University
St Louis, Missouri · Recruiting
Nebraska Methodist Hospital
Omaha, Nebraska · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon · Recruiting
University of Pittsburgh Medical Center-Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
The Univeristy of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Flinders Medical Centre
Bedford Park, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, Australia · Not yet recruiting
Princess Alexandra Hospital
Woolloongabba, Australia · Recruiting
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia · Recruiting
St Vincent'S Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia · Recruiting
Cliniques Universitaires St. Luc
Brussels, Belgium · Recruiting
U.Z. Gent
Ghent, Belgium · Recruiting
Centre Multidisciplinaire de Oncologie Medicale
Liège, Belgium · Recruiting
Hospital de Amor - Barretos
Barretos, Brazil · Recruiting
Hospital Das Clínicas Da Ufmg
Belo Horizonte, Brazil · Recruiting
CIONC
Curitiba, Brazil · Recruiting
Cepon - Centro de Pesquisas Oncologicas
Florianópolis, Brazil · Recruiting
Fundação Amaral Carvalho - Jaú/ Sp
Jaú, Brazil · Recruiting
Icesp - Instituto Do Câncer Do Estado de São Paulo
São Paulo, Brazil · Recruiting
Impar Serviços Hospitalares S.A. - Hospital Nove de Julho
São Paulo, Brazil · Terminated
Hospital A C Camargo
São Paulo, Brazil · Recruiting
Hospital Albert Einstein
São Paulo, Brazil · Recruiting
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.